Anti-Influenza Small Molecule Therapy

Professor Jiayu Liao from the University of California, Riverside has identified small molecules that block the Influenza B virus (IBV) from replicating by inhibiting the SUMOylation pathway. This IBV virus replication inhibition works by using the novel SUMOylation inhibitor, STE025, to inhibit the SUMOylation of the IBV M1 protein. SUMOylation also has active roles in the pathogenesis of several diseases, such as tumorigenesis, neurodegenerative diseases and infections, and as such, this technology could potentially be applied to these types of diseases as well.

Fig 1: Cell death induced by IBV infection can be rescued by the UCR SUMOylation-specific inhibitor, STE025 (blue) compared to cells not exposed to IBV (green), and cells exposed to IBV without the UCR inhibitor (purple and red).

Website

https://techtransfer.universityofcalifornia.edu/NCD/32855.html?utm_source=AUTMGTP&utm_medium=webpage&utm_term=ncdid_32855&utm_campaign=TechWebsites

Potential Applications

  • Small molecule therapy to treat influenza.

Contact Information

Name: Grace Yee

Email: grace.yee@ucr.edu

Phone: 951-827-2212